Provention Bio’s stock flew skyward Tuesday as FDA advisory panel documents apparently backed the efficacy of its diabetes prevention drug teplizumab while avoiding a larger question about the quality of the biotech's manufacturing.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,